What is your treatment approach for a MSS metastatic colorectal cancer patient who has progressed on FOLFOX and FOLFIRI?

If the patient is RAS/BRAF wildtype, then I would pursue anti-EGFR antibody-based therapy. If the patient has KRAS mutant colorectal cancer and continues to have a good performance status, then I would pursue clinical trials if possible. Many of the clinical trials in this space are phase I or phase...